Targets for Ibrutinib Beyond B Cell Malignancies

Area of Science:

• Pharmacology
• Oncology
• Drug Discovery

Background:

• Ibrutinib is an irreversible Bruton's tyrosine kinase (BTK) inhibitor approved for B cell malignancies.
• Initial characterization revealed ibrutinib binds to kinases other than BTK.
• Understanding these off-target interactions is crucial for optimizing treatment and identifying new applications.

Purpose of the Study:

• To review the implications of ibrutinib's off-target kinase interactions.
• To explore how these interactions contribute to both therapeutic effects and adverse events.
• To predict potential new clinical applications based on non-BTK targets.

Main Methods:

• Literature review of ibrutinib's pharmacological profile.
• Analysis of clinical data regarding efficacy and adverse events.
• Exploration of molecular interactions beyond BTK.

Main Results:

• Ibrutinib's clinical outcomes may result from combined inhibition of BTK and other kinases.
• Off-target interactions could explain adverse effects like bleeding and arrhythmias.
• Long-term treatment may impact bone homeostasis via osteoclast inhibition.

Conclusions:

• Ibrutinib's effects extend beyond selective BTK inhibition.
• Off-target binding influences therapeutic efficacy and safety.
• Further research into non-BTK targets may reveal new therapeutic uses for ibrutinib.